David Hallal, Director at iTeos Therapeutics, Inc. (ITOS), sold 229,364 shares at $10.07 ($2.3M) on 2025-06-04, disclosed to the SEC on 2025-06-06.
Scheduled sale ($2.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.07 | 38,227 | $385K | 16.5% |
| 2 | $10.07 | 38,227 | $385K | 16.5% |
| 3 | $10.15 | 38,227 | $388K | 16.7% |
| 4 | $10.15 | 38,227 | $388K | 16.7% |
| 5 | $10.24 | 38,228 | $391K | 16.8% |
| 6 | $10.24 | 38,228 |
| $391K |
| 16.8% |
| Total | $10.15 avg | 229,364 | $2.3M | 100% |
| Filing → |
| ALVR | SELL | 2022-10-21 | $5.1M | — | Filing → |
| ALVR | SELL | 2022-09-30 | $2.9M | — | Filing → |
| ALVR | SELL | 2022-07-21 | $23K | — | Filing → |